Translational Development Acquisition Corp.
TDAC
$10.72
$0.010.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 878.30K | 944.50K | 915.60K | 763.20K | 543.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 878.30K | 944.50K | 915.60K | 763.20K | 543.80K |
| Operating Income | -878.30K | -944.50K | -915.60K | -763.20K | -543.80K |
| Income Before Tax | 6.21M | 6.36M | 4.76M | 3.04M | 1.41M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.21 | 6.36 | 4.76 | 3.04 | 1.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.21M | 6.36M | 4.76M | 3.04M | 1.41M |
| EBIT | -878.30K | -944.50K | -915.60K | -763.20K | -543.80K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.51 | 0.54 | 0.47 | 0.38 | 0.30 |
| Normalized Basic EPS | 0.31 | 0.33 | 0.29 | 0.23 | 0.19 |
| EPS Diluted | 0.51 | 0.54 | 0.47 | 0.38 | 0.30 |
| Normalized Diluted EPS | 0.31 | 0.33 | 0.29 | 0.23 | 0.19 |
| Average Basic Shares Outstanding | 70.38M | 70.38M | 53.89M | 36.03M | 18.18M |
| Average Diluted Shares Outstanding | 70.38M | 70.38M | 53.89M | 36.03M | 18.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |